가와사끼병에서 정맥용 면역글로불린 치료 반응 예측의 한계 = Limitation of Prediction on Intravenous Immunoglobulin Responsiveness in Kawasaki Disease

다국어 초록 (Multilingual Abstract)

Purpose : We aimed to evaluate predictive parameters for non-response to intravenous immunoglobulin (IVIG) in patients with Kawasaki disease (KD) before IVIG use using two controls.
Methods : We evaluated 229 consecutive KD patients who were treated with 2 g/kg of IVIG at a single center. Those who had persistent fever >24 hours after IVIG infusion made up the 23 IVIG non-responders; the first control included a total 206 defervesced cases and the second control included 46 cases that were matched for age and pre-treatment fever duration to non-responders.
Results : Demographic and clinical characteristics were similar in IVIG non-responders and responders at presentation.
As for laboratory findings, the neutrophil differential, CRP, AST, ALT, and LDH were higher, and lymphocyte differential,total protein, albumin, platelet count, and total cholesterol were significantly lower in IVIG non-responders compared to responders by univariate analysis in both study designs. However in multivariate analysis, non-responders showed a significantly higher neutrophil differential (cutoff value, >77%, sensitivity 68.4% and specificity 79.5%) and lower cholesterol (<124mg/dL, sensitivity 79% and specificity 70.5%). Whereas plasma albumin (<3.6 g/dL, sensitivity 73.7% and specificity 60%)was the sole laboratory parameter of non-responders in the second study design.
Conclusion : Severity of inflammation in KD was reflected by higher or lower laboratory values at presentation. Because the multivariate analysis for these indices may be influenced by some confounding factors, including the numbers of patients of different ages and fever duration, other assessment modalities are needed for KD patients with the greatest risk of coronary artery lesions.

국문 초록 (Abstract)

목 적 : 가와사끼병 환자들에서 정맥용 면역글로불린(intravenous immunoglobulin, IVIG) 불응군의 예측지표를 두 대조군을 사용하여 연구하였다.
방 법 : 가톨릭대학교 대전성모병원에서 IVIG 2 g/kg 로 치료한 229명의 가와사끼병 환자들을 대상으로 하였다. 23명 IVIG 불응군(IVIG 투여 후에도 24시간 이상발열이 지속)과, 첫번째 206명의 IVIG 반응군 및 두번째 연령과 치료 전 발열일을 일치시킨 46명의 대조군에대해 임상적, 검사실 소견을 비교하였다.
결 과:인구학적, 임상적 소견은 IVIG 불응군과 반응군이 유사하였다. 검사실 소견에서, 두 가지 연구 모두에서 IVIG 불응군은 반응군에 비해서 중성구 분획, CRP,AST, ALT 그리고, LDH는 유의하게 상승되었고, 림프구 분획, 총 단백질, 알부민, 혈소판 수, 그리고 총 콜레스테롤은 유의하게 저하되어 있었다(단변수분석). 그러나, 다변수분석에서 첫번째 연구에서 높은 중성구 분획(cutoff value, >77%, 민감도 68.4%, 특이도 79.5%)과 낮은 총 콜레스테롤(<124 mg/dL, 민감도 79%, 특이도 70.5%)이, 두번째 연구에서는 알부민(<3.6 g/dL, 민감도 73.7%, 특이도 60%)만이 불응군의 예측 지표로나타났다.
결 론 : 가와사끼병에서 염증의 중증도는 발병 시에 상승되거나 저하된 검사실 소견에 반영된다. 이러한 검사실 지표에 대한 다변수분석은 환아수, 연령 및 발열 기간등의 인자에 의해서 영향을 받으므로, 관상동맥병변의위험이 큰 가와사끼병 환자들을 찾기 위한 다른 접근 방법이 필요하다.

참고문헌 (Reference)

• 1 Wright DA, "Treatment of immunoglobulin-resistant Kawasaki disease with pulsed doses of corticosteroids" 128 : 146-149, 1996
• 2 Furusho K, "Shinomiya K, Hayashidera T, et al. High dose intravenous gamma globulin therapy for Kawasaki syndrome" 2 : 1055-1058, 1984
• 3 Nakano H, "Scoring method for identifying patients with Kawasaki disease at high risk coronary artery aneurysms" 58 : 739-742, 1986
• 4 Tremoulet AH, "Resistance to intravenous immunoglobulin in children with Kawasaki disease" 153 : 117-121, 2008
• 5 Research Committee on Kawasaki disease, "Report of Subcommittee on Standardization of Diagnostic Criteria and Reporting of Coronary Artery Lesions in Kawasaki disease"
• 6 Mori M, "Predictors of coronary artery lesions after intravenous -globulin treatment in Kawasaki γ disease" 137 : 177-180, 2000
• 7 Egami K, "Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease" 149 : 237-240, 2006
• 8 Fukunishi M, "Prediction of nonresponsiveness to intravenous high-dose γ-globulin therapy in patients with Kawasaki disease at onset" 137 : 172-176, 2000
• 9 Sano T, "Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment" 166 : 131-137, 2007
• 10 Kobayashi T, "Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease" 113 : 2606-2612, 2006
• 11 Beiser AS, "Newburger JW. A predictive instrument for coronary artery aneuryms in Kawasaki disease" 81 : 1116-1120, 1998
• 12 Burgner D, "Kawasaki disease: what is the epidemiology telling us about the aetiology?" 9 : 185-194, 2005
• 13 Koren G, "Kawasaki disease: review of risk factors for coronary aneurysms" 108 : 388-392, 1986
• 14 Kawasaki T, "Kawasaki disease. Historical background and current issues" 250 : 1-4, 1987
• 15 Lee KY, "Kawasaki disease may be a hyperimmune reaction of genetically-susceptible children to variants of normal environmental flora" 69 : 642-651, 2007
• 16 Kushner HI, "Kawasaki disease in India: increasing awareness or increased incidence?" 52 : 17-29, 2009
• 17 Harada K, "Intravenous gamma-globulin treatment in Kawasaki disease" 33 : 805-810, 1991
• 18 Burns JC, "Intravenous gamma-globulin treatment and retreatment in Kawasaki disease: US/Canadian Kawasaki Syndrome Study Group" 17 : 1144-1148, 1998
• 19 Burns JC, "Infliximab treatment for refractory Kawasaki syndrome" 146 : 662-667, 2005
• 20 Lee Kyung Yil, "Inflammatory Processes in Kawasaki Disease Reach their Peak at the Sixth Day of Fever Onset: Laboratory Profiles According to Duration of Fever" 대한의학회 19 (19): 501-504, 2004
• 21 Durongpisitkul K, "Immunoglobulin failure and retreatment in Kawasaki diseasae" 24 : 145-148, 2003
• 22 Lee KY, "High-dose intravenous immunoglobulin downregulates the activated levels of inflammatory indices except erythrocyte sedimentation rate in acute stage of Kawasaki disease" 51 : 98-101, 2005
• 23 Lee KY, "Features of Kawasaki disease at the extreams of age" 42 : 423-427, 2006
• 24 Kelley-Hedgepeth A, "Ethnic differences in C-reactive protein concentration" 54 : 1027-1037, 2008
• 25 Du ZD, "Epidemiologic study on Kawasaki disease in Beijing from 2000 through 2004" 26 : 449-451, 2007
• 26 Newburger JW, "Diagnosis, treatment, and longterm management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association" 114 : 1708-1733, 2004
• 27 McCrindle BW, "Coronary artery involvement in children with Kawasaki disease; risk factors from analysis of serial normalized measurements" 116 : 174-179, 2007
• 28 Checchia PA, "Circulating cardiac troponin I levels in Kawasaki disease" 22 : 102-106, 2001
• 29 Hwang JY, "Assessment of intravenous immunoglobulin non-responders in Kawasaki disease" 2010
• 30 Uehara R, "Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan" 27 : 155-160, 2008
• 31 Newberger JW, "A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of Kawasaki syndrome" 324 : 1633-1639, 1991
• 32 Sakata K, "A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease" 16 : 565-571, 2007